Nourish Raises $100 Million at $1.75 Billion Valuation for GLP-1 Nutrition Care

1 articles · Updated · Bloomberg · May 19

$100 million in new Series C funding will help Nourish expand nutrition counseling for people taking GLP-1 weight-loss drugs.
The startup is targeting dietary changes that can boost results from the medications and help preserve those improvements over time.
Menlo Ventures led the round, with existing backers Thrive Capital, Index Ventures and JPMorgan Chase's growth-equity arm also participating.
The financing values Nourish at $1.75 billion, underscoring investor interest in services built around the fast-growing GLP-1 treatment market.

With a $1.75B valuation, is Nourish pioneering a new health standard or just a lucrative dependency on blockbuster drugs?

As giants like Amazon enter GLP-1 care, can specialized startups survive the battle for millions of new patients?

GLP-1 drugs risk 40% muscle loss. Can nutrition coaching prevent turning today's weight loss into tomorrow's frailty?